- Home
- BOF vs LITS Comparison
BOF vs LITS Comparison
Compare BOF & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOF | LITS |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 40.8M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | BOF | LITS |
|---|---|---|
| Price | $4.04 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 87.4K | ★ 282.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,184,018.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.20 | N/A |
| 52 Week Low | $1.53 | $0.95 |
| 52 Week High | $4.95 | $3.03 |
Technical Indicators
Market Signals| Indicator | BOF | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 55.06 |
| Support Level | $2.85 | $1.17 |
| Resistance Level | $4.95 | $1.65 |
| Average True Range (ATR) | 0.31 | 0.07 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 44.59 | 80.95 |
Price Performance
Historical ComparisonAbout BOF BranchOut Food Inc.
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.